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Abstract 22 
Praziquantel is currently the only drug available to treat schistosomiasis. Since drug resistance would 23 
be a major barrier for the increasing global attempts to eliminate schistosomiasis as a public health 24 
problem, efforts should go hand in hand with the discovery of novel treatment options. Synthetic 25 
peroxides might offer a good starting point since their antischistosomal activity has been described in 26 
laboratory studies as well as clinical trials.  We studied 19 bridged 1,2,4,5-tetraoxanes, 2 tricyclic 27 
monoperoxides, 11 bridged 1,2,4-trioxolanes, 12 silyl peroxides, and 4 hydroxylamines against newly 28 
transformed schistosomula and adult Schistosoma mansoni in vitro. Schistosomicidal compounds 29 
were tested for cytotoxicity followed by in vivo studies for the most promising compounds. Tricyclic 30 
monoperoxides, trioxolanes, and tetraoxanes revealed the highest in vitro activity against NTS (IC50s 31 
0.4-20.2 µM) and adult schistosomes (IC50s 1.8-22.8 µM). Tetraoxanes revealed higher cytotoxicity 32 
than antischistosomal activity. Selected trioxolane and tricyclic monoperoxides were tested in mice 33 
harboring an adult S. mansoni infection. Two trioxolanes, compounds 30 and 27, showed moderate 34 
worm burden reductions (WBR) of 44% and 43% (p >0.05), respectively. Compounds of both the 35 
trioxolanes and the tricyclic monoperoxides (compounds 21, 26, 44, and 45) showed low WBRs of 0-36 
27%. Complexation of the compounds with β-cyclodextrin to improve solubility and gastrointestinal 37 
absorption did not increase in vivo antischistosomal efficacy. The high in vitro antischistosomal 38 
activity of trioxolanes and tricyclic monoperoxides are a promising basis for future investigations, 39 
with the focus on improving in vivo efficacy. 40 
41 
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 42 
1. Introduction 43 
Schistosomiasis is a neglected tropical disease, caused in principal by three human Schistosoma 44 
species, S. mansoni, S. haematobium, and S. japonicum. Chemotherapy using praziquantel is the 45 
mainstay of control. Praziquantel is a broad-spectrum antischistosomal agent, and the treatment of 46 
choice since its discovery in the 1970s. Every year millions of people are treated with praziquantel in 47 
the frame of mass drug administration programs. For example, in 2012, 27.5 million people in 21 48 
countries were treated with praziquantel. In 2018, the World Health Organization aims to treat as 49 
many as 235 million people. With increasing drug pressure, the risk for praziquantel resistance or 50 
tolerance is rising.1 Hence, there is a need for new antischistosomal drugs.2,3  51 
In the past years, various semisynthetic and synthetic peroxide classes have been studied for their 52 
antischistosomal properties in laboratory as well as clinical trials, including the artemisinins,4 53 
ozonides (or trioxolanes),5,6 trioxaquines,7 and dioxolanes.8 It has been hypothesized that the 54 
peroxide moiety interferes with heme polymerization, which is responsible for both the 55 
antischistosomal and antimalarial activity.9,10  56 
We recently studied the antischistosomal activity of synthetic peroxides (bridged 1,2,4,5-tetraoxanes, 57 
alphaperoxides, tricyclic monoperoxides) and identified two promising classes, bridged 1,2,4,5-58 
tetraoxanes and tricyclic monoperoxides, which revealed IC50s of 0.3 and 11.8 µM against adult S. 59 
mansoni in vitro and WBRs of 75% and 83% in the S. mansoni mouse model.11   60 
In the present work, we synthesized a new set of bridged 1,2,4,5-tetraoxanes, tricyclic 61 
monoperoxides as well as bridged 1,2,4-trioxolanes, silyl peroxides, and hydroxylamines. The latter 62 
three substance classes were tested for the first time for their antischistosomal activity. Compounds 63 
were first tested against the larval and adult forms of S. mansoni. Compounds showing a promising 64 
antischistosomal activity and a selectivity index <1 in vitro were subsequently tested in vivo. Selected 65 
compounds were additionally packed into β-cyclodextrin with the aim to improve bioavailability. 66 
 67 
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2. Material and methods 68 
2.1. Drugs and media 69 
We studied 19 bridged 1,2,4,5-tetraoxanes, 11 bridged 1,2,4-trioxolanes, 12 silyl peroxides, 2 tricyclic 70 
monoperoxides, and 4 hydroxylamines, and for comparison 2 hit compounds of the previous study11 71 
(Table 1). The 50 compounds were prepared based upon methods described in 72 
literature.12,13,14,15,16,17,18, 19,20  73 
For in vitro evaluations, compounds were prepared as 10 mg/ml stock solutions in dimethyl sulfoxide 74 
(DMSO) (Sigma-Aldrich, Buchs, Switzerland).  75 
Medium 199 and RPMI 1640 were purchased form Life Technologies (Carlsbad, CA), heat inactivated 76 
fetal calf serum (FCS), penicillin, and streptomycin from Lubioscience (Lucerne, Switzerland), and L-77 
glutamic acid from Sigma-Aldrich. β-cyclodextrin for drug complexation was purchased from (Acros, 78 
Belgium). For oral suspension of in vivo testing, compounds not packed in β-cyclodextrin were 79 
suspended in Tween 80 (Fluka, Buchs, Switzerland), ethanol, and H2O (7:3:90), whereas drugs packed 80 
in β-cyclodextrin were suspended in polyethylene glycol 300 (Sigma-Aldrich) and H2O (60:40).  81 
 82 
2.2. Mice and parasites 83 
In vivo studies were approved by the veterinary authorities of Canton Basel-Stadt (license no. 2070), 84 
based on Swiss cantonal and national regulations.  85 
Three week old female NMRI mice (n=62) were purchased from Charles River (Sulzfeld, Germany), 86 
kept at 22°C, 50% humidity, with an artificial 12-hour day/night cycle, and free access to rodent diet 87 
and water. Four-week old mice were infected by subcutaneous injection with 100 S. mansoni 88 
cercariae (Liberian strain), harvested from S. mansoni-infected Biomphalaria glabrata snails. 89 
 90 
2.3. In vitro drug assay on newly transformed schistosomula (NTS) 91 
S. mansoni cercariae were mechanically transformed to newly transformed schistosomula (NTS), and 92 
stored in Medium 199 supplemented with 5% FCS, 100 U/ml penicillin, and 100 µg/ml streptomycin 93 
at 37°C, with 5% CO2, as described previously.
21  94 
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For the NTS drug assay, NTS were added (100/well) to 12.5 µg/ml compound dilutions in 95 
supplemented Medium 199, which were prepared in flat-bottom 96-well plates (BD Falcon, USA). 96 
Compounds that killed the NTS after a 72-h incubation period in at least one well were tested at 97 
lower concentrations (0.4, 0.8, 1.6, 3.1, 6.3, and 12.5 µg/ml) for IC50 determination. NTS exposed to 98 
the highest concentration of DMSO (0.13%) served as control. Assays were performed in triplicate, 99 
and repeated once. Drug activity was evaluated microscopically (Carl Zeiss, Germany; 80-200x 100 
magnification) 72 h post-incubation, using scoring from 3 (normal activity and morphology) to 0 (no 101 
motility, impaired morphology, and granularity).22 102 
2.4. In vitro drug assay on adult S. mansoni 103 
Adult schistosomes were harvested by dissection from mesenteric and hepatic portal veins of 104 
infected mice, seven to nine weeks post-infection. Schistosomes were stored in RPMI 1640 medium 105 
supplemented with 5% FCS, 100 U/ml penicillin, and 100 µg/ml streptomycin, at 37°C with 5% CO2.
6
  106 
For drug activity assessment, adult schistosomes (three of both sexes) were put into 25.0 µg/ml 107 
compound dilutions in supplemented RPMI medium using 24-well flat-bottom plates (BD Falcon). 108 
Schistosomes incubated in the highest concentration of DMSO in culture medium (0.25%) served as 109 
control. Compounds that killed the worms 72 h post-incubation were subsequently tested at lower 110 
concentrations (0.3, 0.9, 2.8, 8.3, and 25.0 µg/ml) for IC50 determination, and scored via microscopic 111 
readout in the same manner as described above for the NTS. Assays were performed in duplicate, 112 
and repeated once.22  113 
 114 
2.5. L6 cytotoxicity drug assay 115 
Rat skeletal myoblast L6 cells (ATCC, Manassas, VA USA) were seeded (2 x 103/well) into 96-well flat-116 
bottom plates (BD Falcon). After a 24-h adherence time, cells were incubated with a 3-fold serial 117 
dilution starting at 90 µg/ml. After 70 h, resazurin (Sigma-Aldrich) was added to the wells, and after 118 
another 2 h, the fluorescence was read using an excitation wavelength of 536 nm and an emission 119 
wavelength of 588 nm (SpectraMax, Molecular Devices; Softmax, version 5.4.1). Cells incubated with 120 
a 3-fold serial dilution of podophyllotoxin (Sigma-Aldrich) starting at 100 ng/ml served as positive 121 
control. IC50 determination was performed in duplicate, and repeated twice.
23 122 
 123 
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2.6. Complexation of drugs with β-cyclodextrin 124 
Compound solutions in acetonitrile (2ml) were mixed into a solution of β-cyclodextrin in H2O and 125 
acetonitrile (70:30; 30ml), with a molar ratio of 1:1 β-cyclodextrin to peroxide. The heterogeneous 126 
mixture was stirred at 20−25°C for 24 h, and the solvent was subsequently removed in a water jet 127 
vacuum pump (Vitlab, Germany). Analytical data are shown in the supplementary file 128 
(Supplementary 1). 129 
2.7. Instrumentation and methods 130 
NMR spectra of compounds were recorded on a Bruker AW-300 (300.13 MHz for 1H, 75.48 MHz for 131 
13C) and Bruker Avance 400 (400.1 MHz for 1H, 100.6 MHz for 13C) in CDCl3 and DMSO-d6. Thin layer 132 
chromatography (TLC) analysis was carried out on standard silica gel chromatography plates. Melting 133 
points determinations were carried out on a Kofler hot-stage apparatus. Chromatography was 134 
performed using silica gel (63−200 mesh and 5-40 µm). Elemental analysis on carbon, hydrogen, and 135 
nitrogen was carried out using a 2400 Perkin-Elmer CHN analyzer. Determination of purity of all 136 
compounds was executed by elemental (combustion) analysis. For all peroxides, deviation from the 137 
theoretical values for C, H, and N content was less than 0.4%. High-resolution mass spectra (HRMS) 138 
were measured by using electrospray ionization (ESI). The measurements were performed in 139 
positive-ion mode (interface capillary voltage 4500 V); the spectra were acquired in the m/z range of 140 
50–3000; the external/internal calibration was done with Electrospray Calibrant Solution. Solutions in 141 
MeCN were injected with a syringe (flow rate 3 ml/min). Nitrogen was applied as a dry gas; the 142 
interface temperature was set at 180°C. These data confirmed >95% purity of all compounds. 143 
Structures of all compounds were confirmed using 1H and 13C NMR spectra. Analytical results of the 144 
unbound compounds as well as the β-cyclodextrin-compound complexes are shown in 145 
supplementary file (Supplementary 1 and 2, respectively).  146 
2.8. In vivo drug assay with S. mansoni-infected mice 147 
Compound suspensions were orally applied to S. mansoni-infected mice (groups of n=4) 49 days 148 
post-infection, at a single dose of 400 mg/kg. Untreated infected mice (n=8) served as control. Mice 149 
were euthanized and dissected 16-21 days post-treatment to count the worms in the portal and 150 
mesenteric veins, and the liver.6 151 
 152 
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2.9. Statistics 153 
Scores of the antischistosomal in vitro drug assays were set in relation to the control values. For in 154 
vitro activities, IC50 values were calculated using CompuSyn software (ComboSyn Inc., USA; version 155 
3.0.1, 2007). R-values represent the linear correlation coefficient, which reflects the conformity or 156 
goodness of the experimental data.24 IC50 and r
2-values of cytotoxicity determination were calculated 157 
by Softmax. IC50s of both antischistosomal activities and cytotoxicity were converted to molarity. 158 
Selectivity indices were calculated by dividing the IC50 of the mammalian cell line by the IC50 of the 159 
antischistosomal activity against adult schistosomes. For in vivo drug efficacy assessment, WBRs were 160 
calculated by comparing worm counts of treated mouse groups to the control group. The Kruskal-161 
Wallis test (StatsDirect Ltd., UK; StatsDirect, version 2.7.2.) was applied for significance 162 
determination (p = 0.05). 163 
 164 
3. RESULTS 165 
3.1. In vitro activity against NTS 166 
Of the 48 compounds tested, 24 killed all NTS in at least one well after 72 h at 12.5 µg/ml. Of these, 167 
compounds 6 and 21 revealed very high (IC50 <1 µM) antischistosomal activities with IC50 values of 168 
0.9 and 0.4 µM, respectively. Twenty compounds showed high (IC50s 1-10 µM) activities (9 169 
tetraoxanes, 7 trioxolanes, 2 tricyclic monoperoxides, and 2 silyl peroxides), and 2 compounds were 170 
characterized by moderate (IC50 >10 µM) antischistosomal activity.  171 
In comparison, in our previous study the most active tetraoxane 20 showed an IC50 at 0.1 µM, the 172 
most active tricyclic monoperoxide 46 at 14.4 µM, and the gold standard praziquantel at 2.2 µM 173 
(Table 2).11  174 
 175 
3.2. In vitro activity against adult S. mansoni 176 
All 48 compounds were tested on adult S. mansoni. Twenty-six compounds killed the worms 177 
following incubation at 25.0 µg/ml for 72 h. Of these, 16 compounds (7 tetraoxanes, 7 trioxolanes, 178 
and 2 tricyclic monoperoxides) revealed high (IC50 1-10 µM) antischistosomal activity. Ten 179 
compounds showed moderate (IC50 >10 µM) activity (6 tetraoxanes, 4 trioxolanes) (Table 2). IC50s of 180 
the hit compounds of our previous study were 0.3 µM for tetraoxane 20, 11.8 µM for tricyclic 181 
monoperoxide 46, and 0.1 µM for praziquantel (Table 2).11 182 
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 183 
3.3. Selectivity of adult S. mansoni-active drugs 184 
Compounds exhibiting IC50s ≤10 µM against adult schistosomes were deemed as potent 185 
schistosomicidals and therefore tested on a mammalian cell line to determine the compound toxicity 186 
and thereof their selectivity (Table 2). Eight compounds indicated selective toxicity towards the 187 
parasite (SI >1), namely compounds 21, 23, 26, 27, 29, 30, 44, and 45, all representatives of the 188 
tricyclic monoperoxide or the trioxolane class. Tetraoxanes were excluded from in vivo studies due to 189 
unselective toxicity. For comparison, the tetraoxanes of the previous study showed SIs ≥5.711  190 
 191 
3.4. In vivo drug efficacy against adult S. mansoni 192 
Four trioxolanes (21, 26, 27, 30) and 2 tricyclic monoperoxides (44, 45) progressed into in vivo studies 193 
based on antischistosomal activity and selectivity. Compound 29 was not considered for in vivo 194 
testing because it showed high structural similarity to compound 27, which had a more promising 195 
antischistosomal profile. Furthermore, compound 23 was excluded because of its higher IC50 and 196 
lower selectivity compared to the other compounds chosen for in vivo studies. 197 
Compounds 30 and 27 showed slight, but not significant (p >0.05), worm burden reductions (WBR) of 198 
44% and 43%, respectively. Compounds 26, 44, 21, and 45 showed low WBRs of 0-27%. Compounds 199 
26, 27, 30, and 44 were prepared as β-cyclodextrin complexes with the aim to improve solubility and 200 
gastrointestinal wall permeation.25 For comparison, two lead molecules (20, 46) from our previous 201 
study11 were also packaged. WBRs of the complexes ranged from 23-36% (p >0.05). Compounds 20 202 
and 46 revealed moderate WBRs of 33% and 36%, respectively. Compounds 26, 27, 30, and 44 of the 203 
present study showed low WBRs between 0-31%. All in vivo results are presented in Table 3.  204 
 205 
4. Discussion 206 
Schistosomiasis is a debilitating disease, affecting hundreds of millions of people living in poor, rural 207 
areas of the subtropics and tropics. Chemotherapy is the mainstay of control, yet there is no 208 
alternative to praziquantel, the gold standard, and no drug is in the clinical pipeline.26 This is a 209 
perilous situation if praziquantel tolerance or resistance should arise.  210 
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Given the promising findings obtained with bridged 1,2,4,5-tetraoxanes and tricyclic monoperoxides 211 
earlier,11 in the present study, we tested a new series of peroxidic compounds, including bridged 212 
1,2,4,5-tetraoxanes, tricyclic monoperoxides, bridged 1,2,4-trioxolanes, silyl peroxides, and 213 
hydroxylamines. We tested 48 compounds (Table 1) in vitro on two stages of S. mansoni, the larval 214 
(NTS) and the adult, and assessed their cytotoxicity using a mammalian cell line. Subsequently, 215 
potent and selective compounds were tested in the S. mansoni mouse model.  216 
Of the 48 compounds tested, 24 compounds killed NTS at 33.3 µM of which 22 revealed high activity 217 
(IC50 ≤10 µM). 26 compounds killed adult S. mansoni at 33.3 µM. 16 of these revealed high activity 218 
(IC50 ≤10 µM). Fourteen compounds showed high activity (IC50s ≤10 µM) against both stages, with 219 
NTS being slightly more affected than adult S. mansoni. The trend of higher sensitivity of NTS against 220 
synthetic peroxides was already observed previously.11 221 
Of the 19 tetraoxanes tested, 7 were highly active and resulted in IC50s ≤10 µM against both NTS and 222 
adult schistosomes. The 4 adamantyl-containing tetraoxanes were the most potent, with IC50 values 223 
down to 2 µM on adult flukes. Replacing the adamantyl moiety with small alkyl substituents lowered 224 
or annihilated the tetraoxanes activity. Placing aryls at the side position lead to loss of activity as 225 
well. For instance, the adamantyl-containing tetraoxane 3 had an IC50 of 3.9 µM, whereas replacing 226 
the adamantyl substituent with an aryl (compound 10) or an isobutyl (compound 5) showed no, or 227 
moderate (IC50 20.8 µM) activity, respectively. Therefore, this set of molecules agrees on the 228 
supporting but not essential nature of adamantyl, which was noted previously.11 Due to unselective 229 
activity however, no tetraoxane was tested in vivo. The toxicity observed with this set of tetraoxanes 230 
is in contrast to our previous findings, where the tested tetraoxanes revealed selectivity (SI ≥5.7).  231 
The 2 tricyclic monoperoxides with simple alkyl substituents showed selective antischistosomal 232 
activity in vitro, but in mice they reduced the S. mansoni worm burden inefficaciously. The reason for 233 
the differing in vivo activity between these two and the previously tested tricyclic monoperoxide 234 
derivative remains to be elucidated.  235 
Of the 11 trioxolanes tested, 5 revealed IC50 values ≤10 µM against larval and adult schistosomes, 236 
which all showed selective schistosomal toxicity. Some trioxolanes were diasteriomers (21, 22; 23, 237 
24; 25, 26; 27, 28; 29, 30), but no consistent configuration-dependent activity was noted. Also the 238 
role of the electron-drawing residue (e.g. halogen or nitrogen dioxide) could not be determined. Two 239 
trioxolanes (30 and 27) were tested in vivo, and resulted in the highest WBRs of this study with 44% 240 
and 43%, respectively, but without significance (p >0.05).  241 
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Hydroxylamines were inactive against both NTS and adult S. mansoni in vitro. Also the newly 242 
synthesized silyl peroxides showed poor to no activity in vitro. Only 2 out of 12 silyl peroxides (32 and 243 
33) revealed activity against NTS with IC50 values ≤10 µM. Poor solubility of these compounds was 244 
observed. 245 
Selected compounds were retested in vivo after their complexation with β-cyclodextrin, since 246 
cyclodextrins are known to improve compound solubility and absorption by biological barrieres, such 247 
as mucosas or skin.25 Nevertheless, observed WBRs of [cyclodextrin-drug] complexes were lower 248 
than free drugs. Likewise, two lead compounds from our previous work resulted in low WBRs. In 249 
general, cyclodextrins can enhance, but also hamper (e.g. with excess cyclodextrin) drug delivery 250 
through biological membranes, hence optimization of the complexation procedure is usually 251 
needed.27 252 
In conclusion, trioxolanes revealed the most potent in vitro schistosomicidal activity and selectivity of 253 
all peroxidic drugs investigated in this study, with moderate in vivo worm burden reductions. 254 
Tetraoxanes and tricyclic monoperoxides, the lead candidates of the previous study, showed high in 255 
vitro antischistosomal activity, but failed demonstrating selectivity, or in vivo efficacy, respectively. 256 
Further modifications on the compounds are necessary to improve in vivo efficacy. 257 
 258 
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TABLES 264 
Table 1  265 
Chemical structures of investigated compounds. 266 
Bridged 1,2,4,5-tetraoxanes 
    
1 2 3 4 
    
5 6 7 8 
    
9 10 11 12 
    
13 14 15 16 
  
12 
    
17 18 19 20* 
Bridged 1,2,4-trioxolanes 
    
21 22 23 24 
    
25 26 27 28 
    
29 30 31  
Silyl peroxides 
  
13 
    
32 33 34 35 
    
36 37 38 39 
    
40 41 42 43 
Tricyclic monoperoxides 
    
44 45 46*  
Hydroxylamines 
  
14 
    
47 48 49 50 
*: Lead compound of previous study (K. Ingram et al, 2012)267 
  
15 
Table 2 268 
Compounds showing antischistosomal activity (killing parasite at 33.3 µM), their L6 cytotoxicity, and 269 
the resulting selectivity index. 270 
 Compound NTS  Adult  L6-cells SI 
  IC50 [µM]  r-value  IC50 [µM]  r-value  IC50 [µM]  r-value  
Praziquantel*  2.2  0.9  0.1 1.9  >96 - >960 
Tetraoxane 20* 0.1  0.9  0.3 1.0  1.7 - 5.7 
Tricyclic 
monoperoxide 46* 14.4  0.8  11.8 0.9  8.2 - 4.9 
Tetraoxanes 1 20.2 0.98  ND -  ND - - 
4 3.7 0.95  7.4 0.94  4.4 1.00 0.6 
7 4.7 0.86  20.9  0.96  ND - - 
9 ND -  12.1 0.97  ND - - 
2 1.3 0.84  2.0 0.90  < 0.4 - < 0.2 
8 1.8 0.93  2.0 0.90  < 0.4 - < 0.2 
6 0.9 0.96  1.8 0.96  1.0 1.00 0.5 
15 1.6 0.90  10.9  0.96  ND - - 
17 ND -  23.6 0.90  ND - - 
16 5.2 0.98  9.8 0.96  2.5 1.00 0.3 
18 3.5 0.90  15.4 0.97  ND - - 
19 1.3 0.88  8.4 0.96  2.5 1.00 0.4 
3 4.0 0.92  3.9 0.96  < 0.4 - < 0.1 
5 ND -  20.8 0.99  ND - - 
Trioxolanes 21 0.4 0.79  1.8 0.89  5.4 0.99 2.9 
22 5.6 1.0  10.3 0.95  ND - - 
23 5.7 0.92  7.0 0.92  22.7 0.97 1.7 
24 7.7 0.99  22.8 0.89  ND - - 
25 ND -  10.0 0.97  ND - - 
26 12.2 0.98  7.4 0.95  15.3 0.98 7.4 
31 ND -  12.2 0.89  ND - - 
27 2.8 0.81  4.2 0.96  2.7 1.00 1.3 
28 3.2 0.92  11.2 0.95  ND - - 
  
16 
29 6.2 0.98  6.6 0.98  7.3 0.97 1.1 
30 2.2 0.92  4.2 1.00  8.1 0.99 1.6 
Tricyclic 
monoperoxides 
44 2.7 0.92  4.4 0.96  24.4 1.00 5.7 
45 2.0 0.88  2.0 0.89  4.9 0.99 3.0 
Silyl peroxides 32 4.0 0.94  ND -  ND - - 
33 7.2 0.88  ND -  ND - - 
ND: not done 271 
SI: selectivity index (cytotoxicity IC50 divided by adult schistosome IC50) 272 
*: Lead compound of previous study (K. Ingram et al, 2012) 273 
 274 
Table 3 275 
In vivo worm burden reductions of S. mansoni-infected mice after a single oral dose of 400 mg/kg. 276 
Compound Number of mice 
tested 
Average worm 
burden (SD) 
Worm burden 
reduction [%] 
Control
1
 8 34.1 (10.3) - 
Control
2
 8 23.6 (11.7) - 
20
*
 6 6.7 (2.5) 75 
46
*
 4 5.3 (5) 83 
30
1
 3 19.0 (4.6) 44 
27
1
 4 19.5 (12.4) 43 
44
1
 3 25.0 (7.0) 27 
26
1
 4 30.8 (8.7) 10 
21
1
 4 32.0 (3.3) 6 
45
1
 4 37.0 (12.5) 0 
[CD-44
2
] 3 16.3 (16.6) 31 
  
17 
[CD-27
2
] 4 22.5 (3.3) 5 
[CD-26
2
] 4 24.5 (6.6) 0 
[CD-30
2
] 3 33.0 (6.7) 0 
[CD-20
2
]
*
 4 33.3 (12.3) 0 
[CD-46
2
]
*
 3 35.7 (18.8) 0 
CD: complexation with β-cyclodextrin 277 
SD: standard deviation 278 
1, 2: batch number of S. mansoni mouse infection 279 
*: Lead compound of previous study (K. Ingram et al, 2012)  280 
281 
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